Linked Life Data

828832

Source:http://linkedlifedata.com/resource/pubmed/id/828832

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1977-5-27
pubmed:abstractText
The 22 nm spherical form of hepatitis B surface antigen was purified from the serum or plasma of chronic carriers of the antigen. Antigens of subtypes ayw and adr were individually prepared by isopycnic banding in cesium chloride followed by rate zonal separation in sucrose. Each preparation was stabilized with human serum albumin, and aliquots were inactivated with 1:2000 formalin at 37 C for 96 hours. The potency and immunogenicity of each preparation were determined: both antigenicity and immunogenicity were retained by the preparations following purification and inactivation. Seronegative chimpanzees were vaccinated with the antigen preparations. None of the vaccinated chimpanzees developed evidence of infection with hepatitis B virus during the follow-up period. Twenty-four weeks after vaccination vaccinated and control chimpanzees were inoculated with live hepatitis B virus. Control chimpanzees developed hepatitis associated with HBs Ag seven and nine weeks following challenge. In contrast, none of the chimpanzees vaccinated with HBs Ag developed HBs Ag or hepatitis. Thus, hepatitis B vaccine appeared to be safe and efficacious when tested in chimpanzees.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0002-9629
pubmed:author
pubmed:issnType
Print
pubmed:volume
270
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
395-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.